Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already cover the safety profile (readOnly, idempotent, non-destructive, openWorld), and the description adds genuinely non-obvious context: the data source is FDA CVM adverse event reports via openFDA, coverage is US-only, and counts are reports rather than confirmed side effects or rates. It also discloses a 1-credit cost. The only gap is that it does not sketch the response shape for a tool with no output schema.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Is the description appropriately sized, front-loaded, and free of redundancy?

The core purpose and example are front-loaded, and each subsequent sentence carries a distinct constraint (source, interpretation caveat, input rule, geography, cost). It is on the dense side but nothing is pure padding; the parenthetical credit note could be trimmed.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a three-parameter read-only aggregation with no output schema, this covers purpose, source, scope, input conventions and interpretation limits. The main remaining unknown is what the returned records look like (reaction label plus count fields), which the description only implies.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

With 100% schema coverage the baseline is 3, but the description adds real meaning: it clarifies that the ingredient must be an active ingredient rather than a brand name, that species filtering is optional (single species only), and that results are ordered most-frequent-first. That goes beyond the schema's field-level descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific verb (counts), a specific resource (reactions reported to FDA for a veterinary medicine active ingredient), and the aggregation/ordering behavior (most frequent first) with a concrete example (carprofen in dogs). It is clearly not the human-drug or supplement reaction tools, so an agent can select it without opening the schema.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Does the description explain when to use this tool, when not to, or what alternatives exist?

Gives the audience and question types it answers (pet owners and vets asking about flea, worming, pain and allergy medicines) and an explicit input rule: search by active ingredient, not brand name. It stops short of naming alternatives (e.g. the human-drug side effect tool or a brand-to-ingredient resolver) as a route when the user supplies a brand name.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.